Another factual information on the “Neuroendocrine Tumor Treatment Market” has as of late added by CMI to its storehouse. This research report offers an inside and out examination of various perspectives, for example, market patterns, pieces of the overall industry, drivers, restrictions, opportunities. It gives an investigative view to settle on further choices in organizations. It covers comprehensive instructive information of various key players working over the globe.
Get FREE Sample Report With Latest Covid19 Analysis @ https://www.coherentmarketinsights.com/insight/request-sample/129
There is an incidence and prevalence of neuroendocrine tumor (NET) owing to multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2), neurofibromatosis type 1 (NF1), Von Hippel-Lindau syndrome (VHL), and tuberous sclerosis complex (TSC) disease, in the U.S. Moreover, based on a study published in the JAMA Oncology Journal, 2017, survival rate of all neuroendocrine tumor treatments have improved, especially for distant-stage gastrointestinal neuroendocrine tumor treatment and pancreatic neuroendocrine tumor treatment. This is majorly due to availability of effective therapies and early diagnosis of the disease. Advent of new therapies and extended indications for approved drugs are again expected to drive growth of the neuroendocrine tumor treatment market.
The global neuroendocrine tumor treatment market is estimated to be valued at US$ 1,448.1 million in 2019 and is expected to exhibit a CAGR of 10.6% during the forecast period (2019-2027).
Advent of new drugs is projected to boost the neuroendocrine tumor treatment market growth
Targeted therapy is one of the most preferred options for the treatment of neuroendocrine tumor. It is an effective approach for the treatment of cancers. Thus, growing adoption of targeted NET therapies is projected to increase over the forecast period, this is further projected to fuel the market growth. Although somatostatins are effective in the treatment of some types of pituitary tumors, regulatory approvals for NET are expected to further encourage its research as a combination therapy with targeted drugs. Pasireotide is another somatostatin analogue under study for the treatment of NET. Somatostain analogs are the preferred therapy for chronic control and are effective for long-term management of the disease. Additionally, Avastin (Bevacizumab), a monoclonal antibody, is being studied for its efficacy in the treatment of carcinoid tumors. It is a gastrin/CCK2 receptor antagonist and is found to shrink tumors in the patients with carcinoid tumors in the stomach and high gastrin levels. Regulatory agencies are focused on providing fast-track and orphan drug status to the potential drug candidates for the treatment of the disease.
Purchase This Premium Report With Discounted Rate: https://www.coherentmarketinsights.com/insight/buy-now/129
The growing number of drug approvals for the treatment of neuroendocrine tumors is projected to drive market growth. For example, in January 2018, Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A. received the U.S. Food and Drug Administration (FDA) approval of its new drug application (NDA) for Lutathera (lutetium Lu 177 dotatate) for the treatment of Somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) including foregut, midgut, and hindgut neuroendocrine tumors, in adults.
However, high cost of development of the therapies or drugs and the side effects associated with the treatment are expected to restrict the market growth over the forecast period. High blood sugar, development of gallstones, and mild digestive system upset such as bloating and nausea are some of the side-effects associated with the treatment of neuroendocrine tumors.
Global Neuroendocrine Tumor Treatment Market- Regional Analysis
On the basis of region, the global neuroendocrine tumor treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is projected to exhibit significant growth in the neuroendocrine tumor treatment market owing to growing approval of novel neuroendocrine tumor treatments in the region. For instance, in December 2014, Ipsen received the U.S. Food and Drug Administration (FDA) approval for its Somatuline Depot (lanreotide) Injection 120 mg, indicated for the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
At the same time, Europe neuroendocrine tumor treatment market is projected to witness significant growth over the forecast period, due to growing product approvals by European Commission (EC) to market the products in the European countries. For instance, in September 2017, the European Commission (EC) approved the Lutathera (lutetium (177Lu) oxodotreotide) for the treatment of patients with unresectable or metastatic, progressive, well-differentiated (grade 1 and grade 2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The approval has allowed marketing of Lutathera in all 28 European Union member states along with Iceland, Norway, and Liechtenstein.
Additionally, growing prevalence of neuroendocrine tumors in Asia Pacific is projected to drive growth of the Asia Pacific neuroendocrine tumor treatment market. For instance, according to the data published by Hutchison Medipharma Limited (Chi-Med), an innovative biopharmaceutical company, in 2018, around 67,600 new cases of neuroendocrine tumor were diagnosed in China. Moreover, currently around 300,000 patients are living with the disease in China. Among these, 80% of the patients are living with non-pancreatic neuroendocrine tumor in China.
Global Neuroendocrine Tumor Treatment Market – Competitive Landscape
Key players operating in the global neuroendocrine tumor treatment market include Pfizer Inc, Novartis AG, Ispen, Advanced Accelerator Applications, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., Hutchison Medipharma Limited, Dauntless Pharmaceuticals Inc., and Exelixis, Inc.
Request Here For PDF Brochure With Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/129
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment Type
- Market Snippet, By Indication
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Mergers and Acquisitions
- Regulatory Scenario
- Reimbursement Scenario
- PEST Analysis
- Porter’s Analysis
- Market Dynamics
- Global Neuroendocrine Tumor Treatment Market, By Treatment Type, 2016-2027, (US$ Million)
-
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Somatostatin Analogues (SSAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Octreotide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Lanreotide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Octreotide
- Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Neuroendocrine Tumor Treatment Market, By Indication, 2016-2027, (US$ Million)
-
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Gastrointestinal NET
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Lung NET
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Pancreatic NET
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Other NET
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Neuroendocrine Tumor Treatment Market, By End User, 2016-2027, (US$ Million)
- Introduction
- Market Share Analysis, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Oncology Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
- Introduction
- Global Neuroendocrine Tumor Treatment Market, By Region, 2016 – 2027, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2019 and 2027 (%)
- Y-o-Y Growth Analysis, By Region, 2017 – 2027
- Regional Trends
- North America
- Market Size and Forecast, By Treatment Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Treatment Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Treatment Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Treatment Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Africa
- Market Size and Forecast, By Treatment Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
- North Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Treatment Type, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Indication, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By End User, 2016 – 2027, (US$ Million)
- Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Introduction
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837